The FDA granted approval for Covidien’s generic kit for the preparation of technetium Tc99m Sestamibi injection use for nuclear myocardial perfusion imaging.
Covidien’s product is a generic version of Cardiolite, which is a myocardial perfusion imaging agent used for detecting coronary artery disease. The branded product is utilized in nearly 60 percent of the 15 million myocardial perfusion imaging studies performed in the U.S. annually.
Technology | October 30, 2008
Generic Tc 99m Sestamibi Cardiac Radiotracer Cleared
Related Content
August 17, 2023 — University of Missouri School of Medicine neurologist Adnan Qureshi, MD recently led a study that ...
August 17, 2023 
July 3, 2023 — According to an accepted manuscript published in ARRS’ own American Journal of Roentgenology (AJR) ...
July 03, 2023 
May 11, 2021 — The American Institute of Ultrasound in Medicine (AIUM) and the American Society of Echocardiography (ASE ...
May 11, 2021 
July 15, 2019 — The U.S. Food and Drug Administration (FDA) has approved Gadavist injection for use in cardiac magnetic ...
July 15, 2019 
Sharon Mulvagh, M.D., FASE, FACC, FRCPC, professor of medicine, division of cardiology, Dalhousie University, Halifax ...
June 28, 2019 
Feature | Contrast Media | Dave Fornell, Editor
Iodine-based contrast agents used in computed tomography (CT) and catheter-based angiography have been implicated as a ...
May 31, 2019 
May 9, 2019 — Osprey Medical announced the launch of DyeMINISH, a global patient registry to evaluate the ongoing safety ...
May 09, 2019 
November 30, 2018 — VigiLanz and Cincinnati Children’s Hospital Medical Center recently announced a collaboration that ...
November 30, 2018 
In February 2018, a workshop was held at the National Institutes of Health (NIH) in Bethesda, Maryland, to explore ...
September 12, 2018 
January 19, 2018 — Ligand Pharmaceuticals Inc. announced initiation of a program to develop contrast agents with reduced ...
January 19, 2018 © Copyright Wainscot Media. All Rights Reserved.
Subscribe Now